Call Traders Swarm Surging Eli Lilly and Co (LLY)

Eli Lilly and Co reached a deal with Zosano Pharma Corp. today

Digital Content Group
Dec 2, 2014 at 2:19 PM
facebook twitter linkedin

Eli Lilly and Co (NYSE:LLY) is surging on an agreement to develop Zosano Pharma Corp.'s osteoporosis treatment, ZP-PTH. At last check, the shares were 3% higher at $70.57, after earlier reaching a 10-year peak of $70.77. Not surprisingly, calls are flying off the shelves at quadruple the normal intraday clip, and short-term strikes are being targeted, as LLY's 30-day at-the-money implied volatility (IV) has risen 4.2% to 15%.

Digging deeper, the pharmaceutical giant's most active option is the weekly 12/5 68.50-strike call, where north of 2,400 contracts have been exchanged. More than three-quarters have crossed at the ask price, and volume outstrips open interest, collectively hinting at buy-to-open activity.

Traders paid a volume-weighted average price (VWAP) of $1.31 for the in-the-money calls. As such, breakeven at this Friday's close -- when the weekly series expires -- is $69.81 (strike plus VWAP). As alluded to, Eli Lilly and Co (NYSE:LLY) is presently perched above this level, suggesting today's buyers are already staring at potential paper profits.


Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!